Neuralink vs Synchron
Side-by-side equity comparison for employees weighing offers at Neuralink or Synchron. Valuations, funding history, headcount growth, and secondary-market context.
| Neuralink | Synchron | |
|---|---|---|
| Latest valuation | $10B | Not publicly disclosed |
| Latest round | Series D | Series C |
| Round date | November 2024 | June 2024 |
| Total raised | $680M | $145M |
| Founded | 2016 | 2016 |
| Headquarters | Fremont, CA | New York, NY |
| Employees | 628 | 15,939 |
| Employee YoY growth | +19% | +5% |
| Primary industry | Healthcare & Biotech | Healthcare & Biotech |
| Secondary-market price | — | — |
| Base-case equity multiple | 1x | 1x |
| Upside equity multiple | 1x | 1x |
| Lead investors | Founders Fund, GV (Google Ventures) | ARCH Venture Partners, Gates Frontier |
| Status | private | private |
Overview
Neuralink develops implantable brain-computer interfaces designed to enable people with paralysis to control digital devices with their thoughts.
Brain-computer interface company developing the Stentrode, a minimally invasive neural implant inserted through blood vessels to enable paralyzed patients to control devices.
Why we compare these
Neuralink appears on Sara's List 2024; Synchron is a direct competitor we track alongside it.
If you're evaluating offers at either one, the equity math depends on more than the headline valuation — dilution, strike price, time to liquidity, and concentration risk all matter. Use our equity compensation calculator and exit calculator to model your own numbers.